Glycomic Therapeutics Market Demand, Investment And Forecast 2028

According to Premium Market Insights new research study on "Glycomic Therapeutics Market is expected to grow from US$ 99,021.46 million in 2021 to US$ 257,578.79 million in 2028; it is estimated to grow with a CAGR of 15.8% from 2022 to 2028.

Get a Sample Copy of This Report@ https://www.premiummarketinsights.com/sample/TIP00073621/?utm_source=OpenPR&utm_medium=10655

Some Of the Major Players Influencing are Intellihep Ltd, Protalix Biotherapeutics, BioMarin Pharmaceutical Inc., Genzyme Corporation (Sanofi), Halozyme Therapeutics, Inc., Bayer AG, Alzheon, Inc., GlycoMar, GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd

The report highlights prevailing trends and factors driving the market growth.
The demand for glycomic therapeutics is attributed to a wide application of glycan-based drugs followed by the development of new treatment processes, increasing research and development in the field of glycomic therapeutics, and rising usage of glycomics-based therapeutics in various diseases leading to the development of new treatment processes.

Wide Application to Treat Various Diseases Followed by Development of New Treatment Processes
Glycan-based therapeutics have wide applications in the pharmaceutical industry; the products are available in different structures & forms and developed as per the application. It is designed for various diseases, such as thrombosis, anemia, cancer, influenza, cataract, and antiinflammation.
The glycoprotein is a type of glycan that can be used to deliver drugs, toxins, or radioactive substances directly to cancer cells. Monoclonal antibodies, including erythropoietin (EPO) and Herceptin (trastuzumab), are widely used across the globeand are part of several research projects. These products are aimed at expanding and improving their applicability and efficacy. Due to its known neuroprotective effects, EPO has been used to treat traumatic brain injury (TBI) in young patients and Alzheimer's disease in rodent models.

Inquiry Before Buying At: https://www.premiummarketinsights.com/inquiry/TIP00073621/?utm_source=OpenPR&utm_medium=10655

The largest and fastest-growing glycomic application category is drug discovery and development, mostly due to the rise in R&D by pharmaceutical and biotechnology firms and the expansion of drug discovery research activities in research institutions. For instance, In April 2020, researchers from the Institute for Glycomics and the University of Adelaide signed an exclusive licensing agreement with Sienna Cancer Diagnostics Ltd. to commercialize a cutting-edge cancer detection tool. The researchers have created SubB2M, a special protein that attaches itself exclusively to a sugar molecule in cancer cells. The protein might revolutionize the area associated with cancer detection.

In March 2021, 48Hour Discovery (48HD) and CQDM announced that the firms received an award of US$ 800,000 for peptide drug development utilizing its unique drug discovery platform. The CQDM Quantum Leap initiative encourages research institutes to dive into establishing cutting-edge technologies, methods, and platforms that expedite drug discovery and development. Merck, a CQDM member, is financing the studies. The University of Alberta and 48HD will work together on the CQDM Quantum Leap initiative project
Additionally, GlycoNet-a Network of Centres of Excellence centered at the University of Alberta for Glycomics Research, provides the funds to enhance Canadians' quality of life.

- In December 2021, researchers at Griffith University's Institute for Glycomics received US$ 2.6 million in funding from the Australian Cancer Research Foundation (ACRF) to establish the ACRF International Centre for Cancer Glycomics. This has boosted their fight against cancer.
- In January 2022, the National Health and Medical Research Council (NHMRC) gave researchers from the Institute of Glycomics grants of more than US$ 1.1 million to help them create new medicines to treat multidrug-resistant gonorrhea infections.
- In March 2022, researchers from the Canadian Glycomics Network (GlycoNet) developed a novel combination medication for Sanfilippo syndrome, which is showing preclinical outcomes.
Researchers at Kaleido Biosciences are developing therapeutics for immune-mediated and inflammatory diseases with synthetic glycans that are selectively metabolized in the gut microbiome to suppress the growth of bacteria associated with inflammation. One synthetic glycan candidate, KB295, is intended to treat ulcerative colitis, an inflammatory bowel disorder (IBD). Further, the administration of microbiome-mediating glycans could radically improve the treatment of IBD sufferers who do not respond to the current standard of care and other patients who have autoimmune and inflammatory conditions by 16%.
These advancements show that glycomics has the potential to provide rapid and accurate therapeutic results for complex conditions. Therefore, the use of glycomics in drug development for various diseases is driving the glycomic therapeutics market.

Order a copy of this research study at- https://www.premiummarketinsights.com/buy/TIP00073621/?utm_source=OpenPR&utm_medium=10655

Various organic and inorganic strategies are adopted by companies operating in the global glycomic therapeutics market. The organic strategies mainly include product launches and product approvals. Further, inorganic growth strategies witnessed in the market are acquisitions, collaborations, and partnerships. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall market growth. Further, acquisition and partnership strategies help the market players strengthen their customer base and expand their product portfolios. A few significant developments by key players operating in the global glycomic therapeutics market are listed below.

- In May 2022, Halozyme Therapeutics announced the completion of its acquisition of Antares Pharma, Inc., with an aim to create specialty products.

- In March 2022, Halozyme Therapeutics announced a global collaboration and license agreement with Chugai Pharmaceutical Co., Ltd. that gave exclusive access to Halozyme's ENHANZE drug delivery technology, a recombinant human hyaluronidase PH20 enzyme (rHuPH20), for an undisclosed target.

A few major primary and secondary sources that were considered while preparing the report on the global glycomic therapeutics market are the American Medical Association, the British Journal of Surgery, and the National Library of Medicine.

Table Of Contents
1. Introduction
1.1 Study Scope
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 Global Glycomic Therapeutics Market - By Class
1.3.2 Global Glycomic Therapeutics Market - By Structures
1.3.3 Global Glycomic Therapeutics Market - By Indications
1.3.4 Global Glycomic Therapeutics Market - By Mode of Action
1.3.5 Global Glycomic Therapeutics Market - By Geography
2. Glycomic Therapeutics Market- Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Global Glycomic Therapeutics Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America - PEST Analysis
4.2.2 Europe - PEST Analysis
4.2.3 Asia Pacific - PEST Analysis
4.2.4 Middle East & Africa - PEST Analysis
4.2.5 South & Central America - PEST Analysis
4.3 Expert Opinion
5. Glycomic Therapeutics Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Wide Application in Various Disorders Followed by the Development of New Treatment Processes
5.1.2 Increasing Research and Development In the Field of Glycomic Therapeutics
5.2 Market Restraints
5.2.1 Shortage of Skilled Professionals and Lack of Research & Development laboratories in Developing Countries.
5.3 Market Opportunities
5.3.1 Wide Applications of Glycomics in Therapeutics
5.4 Future Trends
5.4.1 New Tools in Glycomics Research
5.5 Impact Analysis
Continued…...!

Contact Us:
If you have any queries pertaining to the report or would like further information, feel free to reach out to us at-
Contact Person: Sameer Joshi
E-mail: sales@premiummarketinsights.com
Phone: +1-646-491-9876

About Us:
Premium Market Insights is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost-effective research reports and solutions from various publishers.
The market research industry has changed in last decade. As corporate focus has shifted to niche markets and emerging countries, a number of publishers have stepped in to fulfil these information needs. We have experienced and trained staff that helps you navigate different options and lets you choose best research solution at most effective cost.
Premium Market Insights has an extensive coverage of industry reports, company reports and country reports across all industries. In case your research needs are not met by syndicated reports offered by leading publishers, we can help you by offering a customized research solution by liaising with different research agencies saving your valuable time and money.
We provide best in class customer service and our customer support team is always available to help you on your research queries. Our commitment to customer service is best exemplified by free analyst support that we offer to our clients which sets us apart from any other provider. We also offer enterprise subscriptions which provide significant cost savings to our clients.

This release was published on openPR.